• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells.

作者信息

Yan Lingzhi, Shang Jingjing, Shi Xiaolan, Kang Huizhu, Liu Wei, Xu Nan, Liu Yong, Chen Guanghua, Kang Liqing, Gong Feiran, Tang Fang, Yu Lei, Wu Depei, Fu Chengcheng

机构信息

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Am J Hematol. 2020 Jan;95(1):E20-E23. doi: 10.1002/ajh.25664. Epub 2019 Nov 9.

DOI:10.1002/ajh.25664
PMID:31637745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6972657/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/6972657/ab943f108cc0/AJH-95-E20-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/6972657/ab943f108cc0/AJH-95-E20-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/6972657/ab943f108cc0/AJH-95-E20-g001.jpg

相似文献

1
Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells.通过输注冷冻保存的干细胞成功治疗骨髓瘤CAR T细胞疗法后的骨髓衰竭。
Am J Hematol. 2020 Jan;95(1):E20-E23. doi: 10.1002/ajh.25664. Epub 2019 Nov 9.
2
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗 CD19 CAR T 细胞联合大剂量美法仑和自体干细胞移植治疗难治性多发性骨髓瘤。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.120505.
3
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
4
[The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):341-346. doi: 10.3760/cma.j.cn112138-20200304-00179.
5
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.早期收获和晚期移植作为多发性骨髓瘤的一种有效治疗策略。
Bone Marrow Transplant. 1999 Feb;23(3):221-6. doi: 10.1038/sj.bmt.1701559.
6
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗Richter转化型弥漫性大B细胞淋巴瘤（DLBCL）后出现骨髓衰竭患者的寡克隆T细胞扩增
Blood. 2022 Nov 17;140(20):2175-2179. doi: 10.1182/blood.2022017015.
7
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.多发性骨髓瘤患者首次移植后骨髓持续存在微小残留病时的序贯自体干细胞移植
Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21.
8
CAR T cells - what have we learnt?嵌合抗原受体T细胞——我们学到了什么？
Nat Rev Clin Oncol. 2017 Dec 15;15(1):1. doi: 10.1038/nrclinonc.2017.196.
9
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.抗CD138嵌合抗原受体修饰的T细胞疗法治疗伴有广泛髓外受累的多发性骨髓瘤。
Ann Hematol. 2017 Aug;96(8):1407-1410. doi: 10.1007/s00277-017-3029-3. Epub 2017 Jun 2.
10
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者外周血中浆细胞和造血祖细胞的同时动员。
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.

引用本文的文献

1
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
2
Prolonged haematologic toxicity in CAR-T-cell therapy: A review.嵌合抗原受体 T 细胞疗法的长期血液学毒性：综述。
J Cell Mol Med. 2023 Dec;27(23):3662-3671. doi: 10.1111/jcmm.17930. Epub 2023 Sep 13.
3
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.

本文引用的文献

1
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
2
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
3
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
复发多发性骨髓瘤中靶向 BCMA 疗法的不良反应管理：聚焦综述
J Clin Med. 2023 Aug 25;12(17):5539. doi: 10.3390/jcm12175539.
4
Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.在多发性骨髓瘤中，基于达雷妥尤单抗的诱导治疗后，更高剂量的环磷酰胺可实现最佳的干细胞采集。
Haematologica. 2023 Dec 1;108(12):3502-3505. doi: 10.3324/haematol.2023.283452.
5
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.选择CD34+干细胞增强疗法可安全改善CAR T细胞治疗后的血细胞减少症。
Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572.
6
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.嵌合抗原受体 T 细胞（CAR-T）治疗后持续性中性粒细胞减少症的造血干细胞增强：GLA/DRST 研究。
Blood Adv. 2023 Feb 28;7(4):555-559. doi: 10.1182/bloodadvances.2022008042.
7
Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.CAR-T细胞疗法后的血细胞减少——复杂问题的简要综述
Cancers (Basel). 2022 Mar 15;14(6):1501. doi: 10.3390/cancers14061501.
8
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
9
Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.嵌合抗原受体T细胞疗法治疗淋巴恶性肿瘤后的晚期效应
Transplant Cell Ther. 2021 Mar;27(3):222-229. doi: 10.1016/j.jtct.2020.10.002. Epub 2020 Dec 21.
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
4
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
5
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
6
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 normal lymphocytes.SLAMF7-CAR T 细胞可消除骨髓瘤并选择性杀伤 SLAMF7 正常淋巴细胞。
Blood. 2017 Dec 28;130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub 2017 Oct 31.
7
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
8
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.使用特定比例的CD8+和CD4+ CD19特异性嵌合抗原受体修饰的T细胞对非霍奇金淋巴瘤进行免疫治疗。
Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.
9
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
10
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.用于治疗多发性骨髓瘤的靶向CD19的嵌合抗原受体T细胞
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.